MLTX

Moonlake Immunotherapeutics Stock Analysis

AI Rating

Neutral
  • Quality3/10
  • Growth↓ 2/10
  • Value↑ 5/10
Moonlake Immunotherapeutics sales and earnings growth
MLTX Growth
Fair
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -86.77%
  • FCF Y/Y↓ -67.40%
Moonlake Immunotherapeutics gross and profit margin trends
MLTX Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -112.48%
Moonlake Immunotherapeutics net debt vs free cash flow
MLTX Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -30.7

Moonlake Immunotherapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗